Wal-Mart, the world's largest retailer, has been forced to withdraw 55 drugs from its $4 per month generic prescription drug offer (Marketletters passim) in nine states. A spokesman for the retailer, David Tovar, told the New York Times newspaper that "these states have low-cost laws and we wanted to be in compliance." Local laws in the states in question prohibit the sale of goods below cost as "loss leaders." Wal-Mart stated that the relevant drugs would be priced at $9 for a monthly supply.
Responding to questions about the profitability of the $4 drug offer the executive vice president of the Professional Services Division for Wal-Mart, Bill Simon, said: "it can only be in our program if it is profitable. That's why we do not have the newer, more expensive conversions."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze